Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 14,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Stargardt's Macular Dystrophy
Interventions: avacincaptad pegol, Sham; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 17
States / cities: Phoenix, Arizona • Los Angeles, California • Gainesville, Florida + 14 more

Conditions: Ankle Sprain
Interventions: diclofenac sodium, Matching placebo patch; Drug
Lead sponsor: Cerimon Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Generalized Myasthenia Gravis
Interventions: Batoclimab 680 mg SC weekly, Batoclimab 340 mg SC weekly, Matching Placebo SC, Batoclimab 340 mg SC bi-weekly; Drug
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 30
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Carlsbad, California + 27 more

Conditions: Schizophrenia
Interventions: Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg, Placebo depot, Placebo tablets; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 937 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 39
States / cities: Cerritos, California • Escondido, California • Garden Grove, California + 31 more

Conditions: Congenital Fibrinogen Deficiency, Afibrinogenemia
Interventions: Octafibrin, Haemocomplettan® P or RiaSTAPTM; Biological
Lead sponsor: Octapharma; Industry
Eligibility: 12 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Aurora, Colorado • New Hyde Park, New York

Conditions: Perennial Allergic Rhinitis, PAR
Interventions: ciclesonide nasal aerosol, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 7
States / cities: Costa Mesa, California • Stockbridge, Georgia • Normal, Illinois + 4 more

Conditions: Bipolar Depression
Interventions: cariprazine, placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 26
States / cities: Encino, California • Garden Grove, California • National City, California + 23 more

Conditions: Mild to Moderate Traumatic Brain Injury
Interventions: PoNS Treatment; Device
Lead sponsor: Helius Medical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Colorectal Cancer
Interventions: CRC decision aid pamphlet, Home Safety Pamphlet; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 75 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chalazion
Interventions: OptiLIGHT; Device
Lead sponsor: Lumenis Be Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: New York, New York • Seattle, Washington

Conditions: Back Pain
Interventions: Arbaclofen placarbil, 20 mg, Placebo, Arbaclofen placarbil, 30 mg, Arbaclofen placarbil, 40 mg; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 20
States / cities: Litchfield Park, Arizona • Anaheim, California • San Diego, California + 16 more

Conditions: Obesity, Obstructive Sleep Apnea
Interventions: Maridebart cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Northridge, California • Rolling Hills Estates, California • Brandon, Florida + 10 more

Conditions: Alzheimer's Disease
Interventions: TRx0237 150 mg/day, TRx0237 250 mg/day, Placebo; Drug
Lead sponsor: TauRx Therapeutics Ltd; Industry
Eligibility: Up to 89 Years
Enrollment: 891 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 26
States / cities: Phoenix, Arizona • Laguna Hills, California • Los Angeles, California + 23 more

Conditions: Pneumococcal Disease
Interventions: V116, Placebo, PCV15, PPSV23, PCV15 - Part B; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Ft. Pierce, Florida + 4 more

Conditions: Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
Interventions: Secukinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 100 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Boise, Idaho • Cincinnati, Ohio • Portland, Oregon

Conditions: Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions: 0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS, Vehicle Ophthalmic Solution; Drug
Lead sponsor: Aurinia Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 6 more

Conditions: Asthma
Interventions: Etanercept; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 13
States / cities: Birmingham, Alabama • Denver, Colorado • Sarasota, Florida + 10 more

Conditions: Essential Tremor
Interventions: 100 mg PRAX-944, 60 mg PRAX-944, Placebo, Flexibly dosed 20 mg to 100 mg PRAX-944; Drug
Lead sponsor: Praxis Precision Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 35
States / cities: Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 31 more

Conditions: Eczema
Interventions: Abrocitinib, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 13
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more

Conditions: Ulcerative Colitis
Interventions: TAK-279, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • Murrieta, California • Clearwater, Florida + 13 more

Conditions: Medication Errors and Other Product Use Errors and Issues
Interventions: Med@HOME Mobile App; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Not listed
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Actinic Keratoses
Interventions: PEP005 (ingenol mebutate) Gel, Vehicle gel; Drug
Lead sponsor: Peplin; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 18
States / cities: Mesa, Arizona • Denver, Colorado • Kissimmee, Florida + 14 more

Conditions: General Anesthesia
Interventions: HSK3486, Propofol; Drug
Lead sponsor: Haisco-USA Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 23
States / cities: Sheffield, Alabama • Phoenix, Arizona • Davis, California + 19 more

Conditions: Healthy
Interventions: REGN728; Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Miramar, Florida • Overland Park, Kansas

Search by objective public record fields.

Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

Diclofenac Patch for Treatment of Mild to Moderate Ankle Sprain

Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap

Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis

Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression

PoNS Clinical Experience Program (TBI)

Shared Decision-making and Colorectal Cancer Screening

Evaluation of Effectiveness and Safety of Intense Pulsed Light Treatment for Chalazion

A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)

Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome

Study Evaluating Etanercept in Moderate to Severe Asthma

A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Meds@HOME App to Support Medication Safety

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia

Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy Volunteers